VIDEO: Sozinibercept in ‘last push’ of phase 3 clinical development
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.
Sozinibercept, formerly known as OPT-302, is now in a late-stage program in phase 3 clinical development that is looking at the activity of the molecule to improve visual acuity in patients with neovascular AMD.
“We have our ShORe study testing sozinibercept in combination with ranibizumab. That’s well advanced, looking at about 80% recruitment right now. Our COAST study is in combination with aflibercept and that similarly recruited to about 80%, so we’re in the last push of phase 3 clinical development with the molecule,” Baldwin said.
Editor's note: This article was updated on Nov. 15, 2023, to correct the position title of Megan Baldwin, PhD.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts